E-LIB Suche - Ergebnisse für: Bloem, Lourens T.

1

High cost oncology drugs without proof of added benefit are..:

Brinkhuis, Francine ; Goettsch, Wim G ; Mantel-Teeuwisse, Aukje K.
BMJ. , 2024

2

A Natural Language Processing Approach Towards Harmonized C..:

Verweij, Stefan ; Haverhoek, Vincent ; Bergman, Erik..
Clinical Pharmacology & Therapeutics. 115 (2024) 4 - p. 871-880 , 2024

Link: https://doi.org/10.1002/..

3

Healthcare decision-making for tumour-agnostic therapies in..:

Hogervorst, Milou A. ; van Hattem, Christine C. ; Sonke, Gabe S....
Drug Discovery Today. 29 (2024) 7 - p. 104031 , 2024

Link: https://doi.org/10.1016/..

4

Agreement about Availability of Alternative Treatments for ..:

Madrid Paredes, Jorge ; Versteeg, Jan‐Willem ; Vreman, Rick A..
Clinical Pharmacology & Therapeutics. 116 (2024) 1 - p. 136-146 , 2024

Link: https://doi.org/10.1002/..

5

Added benefit and revenues of oncology drugs approved by th..:

Brinkhuis, Francine ; Goettsch, Wim G ; Mantel-Teeuwisse, Aukje K.
BMJ. , 2024

Link: https://doi.org/10.1136/..

6

Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patien..:

Verschueren, Marjon V. ; Peters, Bas JM. ; Bloem, Lourens T....
Clinical Lung Cancer. 25 (2024) 2 - p. 119-127.e1 , 2024

Link: https://doi.org/10.1016/..

7

Balancing ethical norms and duties for the introduction of ..:

Maksimova, Mariia V. ; van Thiel, Ghislaine J. M. W. ; Tromp, Yke...
Frontiers in Medicine. 11 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

8

Durvalumab after Chemoradiotherapy in Patients with Stage I..:

Verschueren, Marjon V ; Dijs, Talitha ; Gulikers, Judith L...
Immunotherapy. 15 (2023) 11 - p. 839-851 , 2023

Link: https://doi.org/10.2217/..

9

Neonatal pain score after use of paracetamol: Is there a re..:

Berg, Roland B. van den ; Laarman, A.R. Céleste ; Bloem, Lourens T....
Int. Journal of Clinical Pharmacology and Therapeutics. 61 (2023) 8 - p. 354-362 , 2023

Link: https://doi.org/10.5414/..

10

European Conditional Marketing Authorization in a Rapidly E..:

Bloem, Lourens T. ; Schelhaas, Jasmin ; López‐Anglada, Lucía...
Clinical Pharmacology & Therapeutics. 114 (2023) 1 - p. 148-160 , 2023

Link: https://doi.org/10.1002/..

11

Pre‐approval and post‐approval availability of evidence and..:

Bloem, Lourens T. ; Bot, Rosa E. ; Mantel‐Teeuwisse, Aukje K....
British Journal of Clinical Pharmacology. 88 (2022) 5 - p. 2169-2179 , 2022

Link: https://doi.org/10.1111/..

12

Towards diagnostic criteria for malignant deep penetrating ..:

Ebbelaar, Chiel F. ; Schrader, Anne M.R. ; van Dijk, Marijke...
Modern Pathology. 35 (2022) 8 - p. 1110-1120 , 2022

Link: https://doi.org/10.1038/..

13

Genome-wide copy number variations as molecular diagnostic ..:

Ebbelaar, Chiel F. ; Jansen, Anne M. L. ; Bloem, Lourens T..
Virchows Archiv. 479 (2021) 4 - p. 773-783 , 2021

Link: https://doi.org/10.1007/..

14

Associations between uncertainties identified by the Europe..:

Bloem, Lourens T. ; Vreman, Rick A. ; Peeters, Niels W. L....
Clinical and Translational Science. 14 (2021) 4 - p. 1566-1577 , 2021

Link: https://doi.org/10.1111/..

15

Comprehensive evaluation of post-approval regulatory action..:

Bloem, Lourens T. ; Karomi, Mariana ; Hoekman, Jarno...
Expert Opinion on Drug Safety. 20 (2021) 11 - p. 1433-1442 , 2021

Link: https://doi.org/10.1080/..